Chargement en cours...
Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies
The intracellular protein B‐cell‐lymphoma‐2 (BCL2) has been considered an attractive target for cancer therapy since the discovery of its function as a major promoter of cell survival (an anti‐apoptotic) in the late 1980s. However, the challenges of targeting a protein‐protein interaction delayed th...
Enregistré dans:
| Publié dans: | Clin Pharmacol Ther |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5657403/ https://ncbi.nlm.nih.gov/pubmed/27806433 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.553 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|